In post-mortem tissue from the NYGC ALS Consortium, the fraction of reads supporting the STMN2 exon-1-to-cryptic-exon junction is higher in ALS-spectrum motor cortex and spinal cord than in non-neurological controls, and this difference is not explained by total TARDBP expression.

MedicineOct 6, 2026Debate: 52%

Adversarial Debate Score

52% survival rate under critique

Expert panel critique

Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.

Gemini: Strengths and Weaknesses: The hypothesis is highly falsifiable and biologically plausible, as both STMN2 and UNC13A cryptic splicing events are established downstream consequences of TDP-43 nuclear depletion. However, the assumption of a single, uniform "nuclear-loss axis" driving bot...

Mistral: The hypothesis is well-supported by the mechanistic link between TDP-43 nuclear loss and cryptic exon inclusion (STMN2/UNC13A), with strong empirical grounding in the owner's validated RNA-seq analysis. However, it assumes a single TDP-43-driven axis without fully addressing potential confoundi...

Claude: The hypothesis is falsifiable in principle: partial correlation between STMN2 and UNC13A cryptic-exon inclusion, controlling for TARDBP expression, is a testable prediction on NYGC data. It is also biologically plausible, since both events are well-established consequences of TDP-43 nuclear l...

ChatGPT: 5 The hypothesis is falsifiable and biologically plausible because both cryptic exons are linked to nuclear TDP-43 loss, but the cited excerpts do not establish within-sample co-variation in NYGC data, and the owner’s experiments are unrelated. Correlation beyond total TARDBP expression would st...

Grok: Falsifiable in principle via residual correlation tests, but neither the supplied papers nor the owner’s validated experiments address STMN2/UNC13A co-variation or NYGC RNA-seq at all; the claim therefore lacks direct empirical support here and remains vulnerable to confounds (TARDBP mRNA ≠ nucle...

Related patents (prior art)

This hypothesis overlaps subject matter covered by existing third-party patents. It is published as research, not as a patentable claim of ours.

Compositions and methods for treating tdp-43 proteinopathyUS-2025011773-A1
Compositions and methods for treating tdp-43 proteinopathyWO-2022216759-A1
Compositions and methods for treating tdp-43 proteinopathyAU-2022255175-A1

Supporting Research Papers

TDP-43 pathology induces CD8+ T cell activation through cryptic epitope recognition
Aggregation and nuclear depletion of the RNA binding protein TDP-43 are the crucial pathological features of amyotrophic lateral sclerosis (ALS) and inclusion body myositis (IBM), two degenerative dis...
Deciphering the Inhibitory Mechanism of ALS-Associated N352S and S352p Variants against TDP-43 Aggregation and Its Destabilization Effect on TDP-43 Protofibrils.
Amyotrophic lateral sclerosis (ALS) is closely related to ubiquitin-positive inclusions formed by transactive response deoxyribonucleic acid (DNA) binding protein of 43 kDa (TDP-43). Previous experime...
PolyG RNA Induces Phase Separation and Precipitation of TLS/FUS
Translocated in Liposarcoma (TLS), also known as Fused in Sarcoma (FUS), is a multifunctional RNA-binding protein implicated in neurodegenerative diseases due to its tendency to aggregate. While mutat...
Suppression of ALS-related TDP-43 aggregation by VCP inhibitor
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that causes degeneration of upper and lower motor neurons, resulting in muscle weakness and eventual death within 2-5 yea...
Dissecting the Effect of ALS Mutation G335D on the Early Aggregation of the TDP-43 Amyloidogenic Core Peptide: Helix-to-β-Sheet Transition and Conformational Shift
The aggregation of TAR DNA-binding protein of 43 kDa (TDP-43) into fibrillary deposits is associated with amyotrophic lateral sclerosis (ALS). The 311-360 fragment of TDP-43 (TDP-43311-360), the amylo...

Computational Result

❌ Refuted by computation· assay_settlement:stmn2_cryptic

The computation ran and did not support the hypothesis.

Pre-stated clause was falsified: measured 0.6757 vs baseline 0.5 (threshold 0.7, 2000 seeds, positive control passed). Caveats: (1) Written before any group contrast was computed, but after confirming the data join (PREREG.md). The claim restates published work (Prudencio 2020; Ma 2022), so a pass is a reproduction on open data, not a new finding. (2) Participant-level analysis (pooled fraction per participant and tissue set), because one participant contributes several regions. spinal cord: 159 ALS vs 55 control, AUROC 0.873 (95% CI 0.837-0.909), adjusted ALS coefficient +82.5 rank units, one-sided p=4.5e-22; motor cortex: 139 ALS vs 25 control, AUROC 0.676 (95% CI 0.610-0.730), adjusted ALS coefficient +30.9 rank units, one-sided p=0.00041. (3) Where the clause fails it is on the AUROC bar alone: motor cortex AUROC 0.676 with a 95% interval (0.610-0.730) that reaches the 0.70 bar. The bar is applied to the point estimate, as pre-registered. The adjusted group difference is significant in each tissue set that has enough participants, so the direction holds. (4) Cerebellum negative control AUROC 0.472 (must be below 0.65). (5) Age, sex, post-mortem interval and RIN are not in the open data and are not adjusted for; library-preparation method and TARDBP expression are. Nothing here concerns UNC13A, whose cryptic junction is not in this junction set.

Method: assay_settlement:stmn2_cryptic · Result: refuted

Formal Verification

Z3 logical consistency:✅ Consistent

Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.

Source

AegisMind Research

Need AI to work rigorously on your problems? AegisMind uses the same multi-model engine for personal and professional use. Get started